Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 20/20 | 0.72 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | FPR3 | P25089 | 2/20 | 0.47 |
| ▸ | TSPO | P30536 | 2/20 | 0.47 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7965099 | 0.84 | CRHR1 (1.00) | CRHR1TDP1FPR3TSPOTMEM97 | |
| SCHEMBL8617375 | 0.82 | CRHR1 (1.00) | CRHR1TDP1FPR3TSPOTMEM97 | |
| SCHEMBL6295510 | 0.80 | CRHR1 (0.69) | CRHR1FPR3TSPOTMEM97 | |
| SCHEMBL7628525 | 0.80 | CRHR1 (0.72) | CRHR1TDP1FPR3TSPOTMEM97 | |
| SCHEMBL5599759 | 0.77 | CRHR1 (0.87) | CRHR1TDP1FPR3TSPOTMEM97 | |
| SCHEMBL7215696 | 0.75 | CRHR1 (0.69) | CRHR1TDP1FPR3TSPOTMEM97 | |
| SCHEMBL7222252 | 0.75 | CRHR1 (0.69) | CRHR1TDP1FPR3TSPOTMEM97 | |
| SCHEMBL6053303 | 0.73 | CRHR1 (0.52) | CRHR1TDP1 | |
| SCHEMBL6295712 | 0.72 | CRHR1 (0.59) | CRHR1 | |
| SCHEMBL5599495 | 0.71 | CRHR1 (0.50) | CRHR1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2007522200-A | — | — | 2007-08-09 | — | — | JP | claimed |
| EP-1718311-A1 | THERAPEUTIC COMBINATIONS OF ATYPICAL ANTIPSYCHOTICS WITH CORTICOTROPIN RELEASING FACTOR ANTAGONISTS | Pfizer Products Incorporated (US) | 2006-11-08 | — | — | EP | claimed |
| US-20050209250-A1 | Therapeutic combinations of atypical antipsychotics with corticotropin releasing factor antagonists | PFIZER INC | 2005-09-22 | — | — | US | claimed |
| WO-2005079807-A1 | THERAPEUTIC COMBINATIONS OF ATYPICAL ANTIPSYCHOTICS WITH CORTICOTROPIN RELEASING FACTOR ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2005-09-01 | — | — | WO | claimed |
| US-20040082597-A1 | Use of CRF antagonists and related compositions | PFIZER INC | 2004-04-29 | — | — | US | claimed |
| US-20030199527-A1 | Use of corticotropin releasing factor antagonists and related compositions | HAMANAKA ERNEST S (US) | 2003-10-23 | — | — | US | claimed |
| US-20020156089-A1 | Use of CRF antagonists and related compositions | PFIZER INC. | 2002-10-24 | — | — | US | claimed |
| US-6432989-B1 | TREATING SLEEP DISORDERS | PFIZER INC | 2002-08-13 | — | — | US | claimed |
| US-6387894-B1 | MIXTURE OF CORTICOTROPIN RELEASING FACTOR ANTAGINIST AND RENIN-ANGIOTENSIN SYSTEM INHIBITOR; THERAPY FOR CONGESTIVE HEART FAILURE, HYPOTENSIVE AGENTS | PFIZER INC. | 2002-05-14 | — | — | US | claimed |
| US-6384039-B1 | ADMINISTERING CORTICOTROPIN RELEASING FACTOR ANTAGONIST | PFIZER INC. | 2002-05-07 | — | — | US | claimed |
| EP-1149583-A2 | Combinations of corticotropin releasing factor antagonists and growth hormone secretagogues | Pfizer Products Inc. (US) | 2001-10-31 | — | — | EP | claimed |
| US-6248753-B1 | CORTICOTROPIN-RELEASING FACTOR (CRF) ANTAGONISTS | PFIZER INC | 2001-06-19 | — | — | US | claimed |
| US-20010000340-A1 | New uses for corticotropin releasing factor antagonists | CHEN YUHPYNG L (US) | 2001-04-19 | — | — | US | claimed |
| EP-1082960-A2 | Use of CRF antagonists and related compositions for treating depression and modifying the circadian rhytm | Pfizer Products Inc. (US) | 2001-03-14 | — | — | EP | claimed |
| EP-1059100-A2 | Combinations of CRF antagonists and renin-angiotensin system inhibitors | Pfizer Products Inc. (US) | 2000-12-13 | — | — | EP | claimed |
| EP-1040831-A2 | Use of corticotropin releasing factor (CRF) antagonists to prevent sudden death | Pfizer Products Inc. (US) | 2000-10-04 | — | — | EP | claimed |
| EP-0765327-B1 | PYRAZOLO AND PYRROLOPYRIDINES | PFIZER (US) | 1999-07-21 | — | — | EP | claimed |
| EP-0773023-A1 | New uses for corticotropin releasing factor (CRF) antagonists | PFIZER INC. (US) | 1997-05-14 | — | — | EP | claimed |
| EP-0765327-A1 | PYRAZOLO AND PYRROLOPYRIDINES | PFIZER INC. (US) | 1997-04-02 | — | — | EP | claimed |
| WO-1995034563-A1 | PYRAZOLO AND PYRROLOPYRIDINES | PFIZER INC. (US) | 1995-12-21 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050209250-A1 | Therapeutic combinations of atypical antipsychotics with corticotropin releasing factor antagonists | CRH, MC2R, CRHR2 | CRHR1 5/4885TDP1 3496/4885FPR3 752/4885 |
| US-20020156089-A1 | Use of CRF antagonists and related compositions | CRH, CRHR1, CRHR2 | CRHR1 2/4885TDP1 4639/4885FPR3 410/4885 |
| US-20010000340-A1 | New uses for corticotropin releasing factor antagonists | CRH, CRHR1, CRHR2 | CRHR1 2/4885TDP1 3514/4885FPR3 44/4885 |
| US-20030199527-A1 | Use of corticotropin releasing factor antagonists and related compositions | CRH, CRHR1, CRHR2 | CRHR1 2/4885TDP1 3537/4885FPR3 70/4885 |
| US-20040082597-A1 | Use of CRF antagonists and related compositions | CRH, CRHR1, CRHR2 | CRHR1 2/4885TDP1 4639/4885FPR3 410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.